Targeting KRAS in cancer

A Singhal, BT Li, EM O'Reilly - Nature Medicine, 2024 - nature.com
RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …

Impact of context-dependent autophagy states on tumor progression

M Assi, AC Kimmelman - Nature cancer, 2023 - nature.com
Macroautophagy is a cellular quality-control process that degrades proteins, protein
aggregates and damaged organelles. Autophagy plays a fundamental role in cancer where …

Combinatorial strategies to target RAS-driven cancers

N Perurena, L Situ, K Cichowski - Nature Reviews Cancer, 2024 - nature.com
Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …

Cancer takes many paths through G1/S

ES Knudsen, AK Witkiewicz, SM Rubin - Trends in Cell Biology, 2023 - cell.com
In the commonly accepted paradigm for control of the mammalian cell cycle, sequential
cyclin-dependent kinase (CDK) and cyclin activities drive the orderly transition from G1 to S …

Treatment strategies for KRAS-mutated non-small-cell lung cancer

É O'Sullivan, A Keogh, B Henderson, SP Finn, SG Gray… - Cancers, 2023 - mdpi.com
Simple Summary KRAS plays an important role in transmitting signals from growth factors on
the outside of the cell to the cell nucleus. It regulates cell proliferation, growth, and survival …

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer

D Wei, L Wang, X Zuo, A Maitra, RS Bresalier - Clinical Cancer Research, 2024 - AACR
KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

A Yousef, M Yousef, S Chowdhury, K Abdilleh… - NPJ Precision …, 2024 - nature.com
The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in
pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients …

Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer

X Liu, B Luo, X Wu, Z Tang - Biochimica et Biophysica Acta (BBA)-Reviews …, 2023 - Elsevier
Breast cancer is one of the most common malignant tumors in women worldwide, and thus, it
is important to enhance its treatment efficacy [1]. Copper has emerged as a critical trace …

Targeting KRAS in pancreatic ductal adenocarcinoma: The long road to cure

VHF de Jesus, MC Mathias-Machado, JPF de Farias… - Cancers, 2023 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma is one of the deadliest malignancies in
humans. Despite advances in systemic therapy, prognosis still remains poor. However …

Six‐Membered Aromatic Nitrogen Heterocyclic Anti‐Tumor Agents: Synthesis and Applications

J Li, A Gu, XM Nong, S Zhai, ZY Yue… - The Chemical …, 2023 - Wiley Online Library
Cancer stands as a serious malady, posing substantial risks to human well‐being and
survival. This underscores the paramount necessity to explore and investigate novel …